The mission of Regenerex, LLC, is to make the facilitating cell platform technology (FCRx) widely available to treat many disorders with unmet need. The FCRx product eliminates the need for a perfectly matched donor, thereby allowing nearly any candidate for a stem cell transplant to receive the treatment.

Hematopoietic stem cell transplantation (HSCT) has been used to successfully treat inherited metabolic enzyme disorders, red blood cell disorders (sickle cell disease and thalassemia), to induce tolerance to organ transplants and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis and scleroderma.”